Skip to main content
Top
Published in: Clinical Rheumatology 11/2019

01-11-2019 | Rheumatoid Arthritis | Original Article

LncRNA GAS5 overexpression downregulates IL-18 and induces the apoptosis of fibroblast-like synoviocytes

Authors: Cuili Ma, Weigang Wang, Ping Li

Published in: Clinical Rheumatology | Issue 11/2019

Login to get access

Abstract

Background

Long non-coding RNA (lncRNA) growth arrest specific transcript 5 (GAS5) negatively regulates interleukin-18 (IL-18) in ovarian cancer, while IL-18 contributes to the development of rheumatoid arthritis (RA). Therefore, GAS5 may also participate in RA.

Methods

GAS5 and IL-18 in plasma of RA patients (n = 60) and healthy controls (n = 60) were measured by RT-qPCR and ELISA, respectively. Linear regression was performed to analyze the correlations between plasma levels of IL-18 and GAS5 in both RA patients and healthy controls.

Results

In the present study, we found that plasma GAS5 was downregulated, while IL-18 was upregulated in RA patients than in healthy controls. A significant and inverse correlation between GAS5 and IL-18 was found in RA patients but not in healthy controls. IL-18 treatment did not significantly alter the expression of GAS5 in fibroblast-like synoviocytes, while GAS5 overexpression led to the inhibited expression of IL-18. GAS5 overexpression also resulted in the promoted apoptosis of fibroblast-like synoviocytes.

Conclusions

Therefore, GAS5 overexpression may improve RA by downregulating IL-18 and inducing the apoptosis of fibroblast-like synoviocytes.
Key points
The present study mainly showed that overexpression of GAS5 may assist the treatment of RA.
The mechanism of GAS5 for the treatment of RA involves the downregulating inflammatory IL-18 and mediating the apoptosis of fibroblast-like synoviocytes.
GAS5 and IL-8 were correlated in RA patients but not in healthy controls.
Literature
1.
go back to reference Picerno V, Ferro F, Adinolfi A, Valentini E, Tani C, Alunno A (2015) One year in review: the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 33:551–558PubMed Picerno V, Ferro F, Adinolfi A, Valentini E, Tani C, Alunno A (2015) One year in review: the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 33:551–558PubMed
2.
go back to reference Catrina AI, Joshua V, Klareskog L, Malmstrom V (2016) Mechanisms involved in triggering rheumatoid arthritis. Immunol Rev 269:162–174CrossRef Catrina AI, Joshua V, Klareskog L, Malmstrom V (2016) Mechanisms involved in triggering rheumatoid arthritis. Immunol Rev 269:162–174CrossRef
3.
go back to reference O’Dwyer DN, Armstrong ME, Cooke G, Dodd JD, Veale DJ, Donnelly SC (2013) Rheumatoid arthritis (RA) associated interstitial lung disease (ILD). Eur J Intern Med 24:597–603CrossRef O’Dwyer DN, Armstrong ME, Cooke G, Dodd JD, Veale DJ, Donnelly SC (2013) Rheumatoid arthritis (RA) associated interstitial lung disease (ILD). Eur J Intern Med 24:597–603CrossRef
4.
go back to reference Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. Immunity. 46(2):183–196CrossRef Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. Immunity. 46(2):183–196CrossRef
5.
go back to reference McInnes IB, Schett G (2017) Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 389(10086):2328–2337CrossRef McInnes IB, Schett G (2017) Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 389(10086):2328–2337CrossRef
6.
go back to reference Hitchon CA, El-Gabalawy HS (2011) Suppl 1: the synovium in rheumatoid arthritis. Open Rheumatol J 5:107–114CrossRef Hitchon CA, El-Gabalawy HS (2011) Suppl 1: the synovium in rheumatoid arthritis. Open Rheumatol J 5:107–114CrossRef
7.
go back to reference Bartok B, Firestein GS (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233(1):233–255CrossRef Bartok B, Firestein GS (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233(1):233–255CrossRef
8.
go back to reference Zhang Y, Xu YZ, Sun N, Liu JH, Chen FF, Guan XL, Li A, Wang F, Zhao QF, Wang HY, Song SS, Yu W, Zhao JN, Li XJ (2016) Long noncoding RNA expression profile in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Res Ther 18(1):227CrossRef Zhang Y, Xu YZ, Sun N, Liu JH, Chen FF, Guan XL, Li A, Wang F, Zhao QF, Wang HY, Song SS, Yu W, Zhao JN, Li XJ (2016) Long noncoding RNA expression profile in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Res Ther 18(1):227CrossRef
9.
go back to reference Ye Y, Gao X, Yang N (2018) LncRNA ZFAS1 promotes cell migration and invasion of fibroblast-like synoviocytes by suppression of miR-27a in rheumatoid arthritis. Hum Cell 31(1):14–21CrossRef Ye Y, Gao X, Yang N (2018) LncRNA ZFAS1 promotes cell migration and invasion of fibroblast-like synoviocytes by suppression of miR-27a in rheumatoid arthritis. Hum Cell 31(1):14–21CrossRef
10.
go back to reference Li J, Yang C, Li Y, Chen A, Li L, You Z (2018) LncRNA GAS5 suppresses ovarian cancer by inducing inflammasome formation. Biosci Rep 38(2):BSR20171150CrossRef Li J, Yang C, Li Y, Chen A, Li L, You Z (2018) LncRNA GAS5 suppresses ovarian cancer by inducing inflammasome formation. Biosci Rep 38(2):BSR20171150CrossRef
11.
go back to reference Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB (1999) A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104(10):1393–1401CrossRef Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB (1999) A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104(10):1393–1401CrossRef
12.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581CrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581CrossRef
13.
go back to reference Lee SY, Kwok SK, Son HJ et al (2013) IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis res Ther 15(1):R31CrossRef Lee SY, Kwok SK, Son HJ et al (2013) IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis res Ther 15(1):R31CrossRef
14.
go back to reference McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219CrossRef McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219CrossRef
15.
go back to reference Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67(11):1516–1523CrossRef Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67(11):1516–1523CrossRef
16.
go back to reference Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164(5):2832–2838CrossRef Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164(5):2832–2838CrossRef
17.
go back to reference Petrovic-Rackov L, Pejnovic N (2006) Clinical significance of IL-18, IL-15, IL-12 and TNF-α measurement in rheumatoid arthritis. Clin Rheumatol 25(4):448–452CrossRef Petrovic-Rackov L, Pejnovic N (2006) Clinical significance of IL-18, IL-15, IL-12 and TNF-α measurement in rheumatoid arthritis. Clin Rheumatol 25(4):448–452CrossRef
18.
go back to reference Hu J, Wu H, Wang D, Yang Z, Dong J (2019) LncRNA ANRIL promotes NLRP3 inflammasome activation in uric acid nephropathy through miR-122-5p/BRCC3 axis. Biochimie 157:102–110CrossRef Hu J, Wu H, Wang D, Yang Z, Dong J (2019) LncRNA ANRIL promotes NLRP3 inflammasome activation in uric acid nephropathy through miR-122-5p/BRCC3 axis. Biochimie 157:102–110CrossRef
19.
go back to reference Pickard MR, Williams GT (2016) The hormone response element mimic sequence of GAS5 lncRNA is sufficient to induce apoptosis in breast cancer cells. Oncotarget 7(9):10104–10116CrossRef Pickard MR, Williams GT (2016) The hormone response element mimic sequence of GAS5 lncRNA is sufficient to induce apoptosis in breast cancer cells. Oncotarget 7(9):10104–10116CrossRef
Metadata
Title
LncRNA GAS5 overexpression downregulates IL-18 and induces the apoptosis of fibroblast-like synoviocytes
Authors
Cuili Ma
Weigang Wang
Ping Li
Publication date
01-11-2019
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 11/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04691-2

Other articles of this Issue 11/2019

Clinical Rheumatology 11/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.